What’s at Stake as Beijing Beats Global Peers with First Approval of Novel Therapy Beijing's approval of a novel therapy for narcolepsy type 1 marks a significant milestone in the country's push to accelerate rare disease treatments.
This achievement raises questions about the implications of China's rapidly evolving regulatory environment on global healthcare.
The Double Edged Sword of Speed The National Medical Products Administration (NMPA) has greenlit commercial sales of this therapy, demonstrating Beijing's willingness to streamline the approval process for novel drugs.